Remove Hormones Remove Production Remove Radiology
article thumbnail

CHMP Recommends Third Indication for Bayer’s Nubeqa in Advanced Prostate Cancer Patients

The Pharma Data

The new recommendation supports the use of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the European Union (EU). Results from the ARANOTE trial show darolutamide plus ADT significantly reduces the risk of radiological progression or death.

article thumbnail

Patient Safety and Radiopharmaceuticals Administration: Minimizing Radiation Exposure and Risks

Worldwide Clinical Trials

Hormonal Status : A body’s hormones, such as levels of reproductive hormones and thyroid function, can impact tissue responses to radiation therapy. It also oversees Good Manufacturing Practices (GMP) for radiopharmaceutical production facilities to ensure consistent quality and safety standards.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bayer delivers on medical innovation fueling transformation of pharma business

The Pharma Data

Our leadership in cardiology, radiology and women’s health is recognized worldwide, and we are expanding our presence in oncology, working tirelessly to bring forward new approaches that can change the treatment paradigm for patients,” said Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Pharmaceuticals Division.

article thumbnail

Hypoxia-Inducible Factor-2 Alpha (HIF-2?) Inhibitor WELIREG™ (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors

The Pharma Data

Advise patients of these risks and the need for effective non-hormonal contraception. WELIREG can render some hormonal contraceptives ineffective. Merck is working to optimize production of WELIREG to allow for a sustainable supply to meet anticipated U.S. WELIREG can render some hormonal contraceptives ineffective.

article thumbnail

A USD 4.2 Billion Myovant/ Pfizer Deal; Audentes Therapeutics’ ASPIRO Trial Free to Proceed; First Generic of Drug for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica

Delveinsight

Relugolix is a once-daily, oral gonadotropin-release hormone (GnRH) receptor antagonist. To overcome this, Glucagon, a hormone in the body, helps the liver to quickly increase blood sugar levels. Teleflex Incorporated has finally completed the acquisition of Z-Medica, an industry-leading manufacturer of hemostatic products.

article thumbnail

Meeting public expectations of diagnostics is the next big test for the NHS

pharmaphorum

Before COVID, the UK spent £12 per head on IVD products – around half that of Germany and two thirds of France – according to MedTech Europe. Again, before the pandemic, the UK carried out around 900 million tests each year and was a net exporter of IVD products. However, COVID has been a game-changer in more ways than one.

article thumbnail

Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio® at St. Gallen Virtual Congress 2021

The Pharma Data

Symptoms may include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams. There are no data on the presence of Verzenio in human milk or its effects on the breastfed child or on milk production. Patients should avoid grapefruit products. Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis.

HR